Researchers at the Virginia Commonwealth University’s Masey Cancer Center have developed an innovative approach to the treatment of multiple myeloma. The Phase II Clinical trial involves a process to ‘mark’ cancerous cells and also boost the body’s immune system – by removing the patient’s stem cells, manipulating them in-vitro [outside the body] and then reintroducing the stem cells back into the patient - to destroy the cancerous cells. Researchers believe the reprogrammed stem cells will also prevent any future recurrence of multiple myeloma.
